Mesenchymal stem cell pretreatment of non-heart-beating-donors in experimental lung transplantation

Journal of Cardiothoracic Surgery

Volumn 9, Issue 1, 2014, Pages

  Wittwer, Thorsten ^a   Rahmanian, Parwis ^a   Choi, Yeong Hoon ^a   Zeriouh, Mohamed ^a   Karavidic, Samira ^a   Neef, Klaus ^a   Christmann, Astrid ^b   Piatkowski, Tanja ^b   Schnapper, Anke ^b   Ochs, Matthias ^b,c   Mühlfeld, Christian ^b,c   Wahlers, Thorsten ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c Cluster of Excellence REBIRTH (From Regenerative Biology to Reconstructive Therapy)   (Germany)

Author keywords

Donor pretreatment; Ischemia reperfusion injury; Mesenchymal stem cell therapy; Non heart beating donors; Perfadex lung preservation

Indexed keywords

EID: 84908088692     PISSN: None     EISSN: 17498090     Source Type: Journal    
DOI: 10.1186/s13019-014-0151-3     Document Type: Article

References (61)

1. Christie JD, Edwards LB, Kucheryavaya AY, Benden C, Dobbels F, Kirk R, Rahmel A, Stehlik J, Hertz MI. J Heart Lung Transplant 2011, 30(10):1104-1122. 10.1016/j.healun.2011.08.004, 21962018.
2. Wittwer T, Franke UFW, Fehrenbach A, Ochs M, Sandhaus T, Pfeifer F, Dreyer N, Knudsen L, Mueller T, Schubert H, Richter J, Wahlers T. Innovative pulmonary preservation of Non-heart-beating donor grafts in experimental lung transplantation. Eur J Cardiothorac Surg 2004, 26:144-150. 10.1016/j.ejcts.2004.01.039, 15200993.
3. Egan T. Non-heart-beating donors in thoracic transplantation. J Heart Lung Transplant 2004, 23:3-10. 10.1016/S1053-2498(02)00658-7, 14734121.
4. Dark JH. Lung transplantation from the Non-heart beating donor. Transplantation 2008, 86:200-201. 10.1097/TP.0b013e31817c87b6, 18645477.
5. Van De Wauwer C, Verschuuren EAM, van der Bij W, Nosssent GD, Erasmus ME. The use of non-heart-beating lung donors category III can increase the donor pool. Eur J Cardio-thorax Surg 2011, 39:e175-e180. 10.1016/j.ejcts.2011.01.035.
6. Gomez-de-Antonio D, Varela A. Non-heart-beating donation in Spain. Gen Thorac Cardiovasc Surg 2011, 59:1-5. 10.1007/s11748-010-0661-4, 21225392.
7. Lee JC, Christie JD. Primary graft dysfunction. Proc Am Thorac Soc 2009, 6:39-46. 10.1513/pats.200808-082GO, 19131529.
8. Warnecke G, Haverich A. Lung re-transplantation: a review. Curr Opin Organ Transplant 2012, 17(5):485-489. 10.1097/MOT.0b013e328357d8ba, 22907540.
9. LaPar DJ, Laubach VE, Emaminia A, Crosby IK, Hajzus VA, Sharma AK, Sumner HM, Webb DV, Lau CL, Kron IL. Pretreatment strategy with adenosine A2A receptor agonist attenuates reperfusion injury in a preclinical porcine lung transplantation model. J Thorac Cardiovasc Surg 2011, 31:1-8.
10. Pego-Fernandes PM, Samano MN, Fiorelli AI, Camargo SM, Xavier AM, Sarmento PA, Bernardo WM. Ribeiro de castro MC, Jatene FB. Recommendations for the Use of extended criteria donors in lung transplantation. Transplant Proc 2011, 43:216-219. 10.1016/j.transproceed.2010.12.050, 21335191.
11. Schiavon M, Falcoz PE, Santelmo N, Massard G. Does the use of extended criteria donors influence early and long-term results of lung transplantation?. Interact Cardiovasc Thorac Surg 2012, 14(2):183-187. 10.1093/icvts/ivr079, 22159257.
12. Wittwer T, Franke UFW, Fehrenbach A, Ochs M, Sandhaus T, Schuette A, Richter S, Dreyer N, Knudsen L, Mueller T, Schubert H, Richter J, Wahlers T. Donor pretreatment using the aerosolized prostacyclin analogue Iloprost optimizes postischemic function of Non heart beating donor lungs. J Heart Lung Transplant 2005, 24:371-378. 10.1016/j.healun.2004.02.014, 15812907.
13. Dong BM, Abano JB, Egan TM. Nitric Oxide ventilation of rat lungs from non-heart-beating donors improves posttransplant function. Am J Transplant 2009, 9(12):2707-2715. 10.1111/j.1600-6143.2009.02840.x, 19845592.
14. Ochs M, Nenadic I, Fehrenbach A, Albes JM, Wahlers T, Richter J, Fehrenbach H. Ultrastructural alterations in intraalveolar surfactant subtypes after experimental ischemia and reperfusion. Am J Respir Crit Care Med 1999, 160:718-724. 10.1164/ajrccm.160.2.9809060, 10430751.
15. Ochs M, Fehrenbach H, Nenadic I, Bando T, Fehrenbach A, Schepelmann D, Albes JM, Wahlers T, Richter J. Preservation of intraalveolar surfactant in a rat lung ischaemia/reperfusion injury model. Eur Respir J 2000, 15:526-531. 10.1034/j.1399-3003.2000.15.16.x, 10759447.
16. Knudsen L, Waizy H, Fehrenbach H, Richter J, Wahlers T, Wittwer T, Ochs M. Ultrastructural changes oft the intracellular surfactant pool in a rat model of lung transplantation-related events. Respir Res 2011, 12:79-89. 10.1186/1465-9921-12-79, 21669009.
17. Novick RJ, Gehman KE, Ali IS, Lee J. Lung preservation: the importance of endothelial and alveolar type II cell integrity. Ann Thorac Surg 1996, 62:302-314. 10.1016/0003-4975(96)00333-5, 8678672.
18. Wong AP, Dutly AE, Sacher A, Lee H, Hwang DM, Liu M. Targeted cell replacement with bone marrow cells for airway epithelial regeneration. Am J Physiol Lung Cell Mol Physiol 2007, 293:L740-L752. 10.1152/ajplung.00050.2007, 17616650.
19. Zhen G, Xue Z, Zhao J, Gu N, Tang Z, Xu Y, Zhang Z. Mesenchymal stem cell transplantation increases expression of vascular endothelial growth factor in papain-induced emphysematous lungs and inhibits apoptosis of lung cells. Cytotherapy 2010, 12:605-614. 10.3109/14653241003745888, 20429787.
20. Walker N, Badri L, Wettlaufer S, Flint A, Sajjan U, Krebsbach PH, Keshamouni VG, Peters-Golden M, Lama VN. Resident tissue specific mesenchymal progenitor cells contribute to fibrogenesis in human lung allografts. Am J Pathol 2011, 178:2461-2469. 10.1016/j.ajpath.2011.01.058, 21641374.
21. Walker NM, Badri LN, Wadhwa A, Wettlaufer S, Peters-Golden M, Lama VN. Prostaglandin E2 as an inhibitory modulator of fibrogenesis in human lung allografts. Am J Crit Care Med 2012, 185(1):77-84. 10.1164/rccm.201105-0834OC.
22. Selmani Z, Naji A, Obert L, Tiberghien P, Rouas-Freiss N, Carosell ED, Deschaseaux F. HLA-G is a crucial immunosuppressive molecule secreted by adult human mesenchymal stem cells. Transplantation 2009, 87:S62-S66. 10.1097/TP.0b013e3181a2a4b3, 19424010.
23. Wang Y, Cristostomo PR, Wang M, Markel TA, Novotny NM, Meldrum DR. TGF-alpha increases increases human mesenchymal stem cell-secreted VEGF by MEK- and PI3-K- but not JNK- or ERK-dependent mechanisms. Am J Physiol Regul Integr Comp Physiol 2008, 295:R1115-R1123. 10.1152/ajpregu.90383.2008, 18685072.
24. Ortiz LA, Gambelli F, McBride C. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci U S A 2003, 100:8407. 10.1073/pnas.1432929100, 12815096.
25. Devine SM, Bartholomew AM, Mahmud N. Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. Exp Hematol 2001, 29:244. 10.1016/S0301-472X(00)00635-4, 11166464.
26. Popp FC, Eggenhofer E, Renner P, Geissler EK, Piso P, Schlitt HJ, Dahlke MH. Mesenchymal stem cells can affect solid organ allograft survival. Transplantation 2009, 87:S57-S62. 10.1097/TP.0b013e3181a288aa, 19424009.
27. Kanazawa H, Fujimoto Y, Teratani T, Iwasaki J, Kasahara N, Negeshi K, Tsuruyama T, Uemoto S, Kobayashi E. Bone marrow-derived mesenchymal stem cells ameliorate hepatic ischemia reperfusion injury in a Rat model. PLoS One 2011, 6:e19195. 10.1371/journal.pone.0019195, 21559442.
28. Neef K, Choi YH, Weichel A, Rahmanian PB, Liakopoulos OJ, Stamm C, Choi CY, Jacobshagen C, Wittwer T, Wahlers T. The influence of cardiovascular risk factors on bone marrow mesenchymal stromal cell fitness. Cytotherapy 2012, 14(6):670-678. 10.3109/14653249.2012.663483, 22404082.
29. Dahlke MH, Hoogduijn M, Eggenhofer, Popp FC, Renner P, Slowik P, Rosenauer A, Piso P, Geissler EK, Lange C, Chabannes D, Mazzanti B, Bigenzahn S, Bertolino P, Kunter U, Introna M, Rambaldi A, Capelli C, Perico N, Casiraghi F, Noris M, Gotti E, Seifert M, Saccardi R, Verspaget HW, van Hoek B, Bartholomew A, Wekerle T, Volk HD, Remuzzi G, Deans R, Lazarus H, Schlitt HJ, Baan CC. Toward MSC in solid organ transplantation: 2008 position paper of the MISOT study group. Transplantation 2009, 88:614-619. 10.1097/TP.0b013e3181b4425a, 19741455.
30. Scherle W. A simple method for volumetry of organs in quantitative stereology. Mikroskopie 1970, 26:57-60. 5530651.
31. Ochs M. A brief update on lung stereology. J Microsc 2006, 222:188-200. 10.1111/j.1365-2818.2006.01587.x, 16872418.
32. Weibel ER, Hsia CCW, Ochs M. How much is there really? Why stereology is essential in lung morphometry. J Appl Physiol 2007, 102:459-467. 10.1152/japplphysiol.00808.2006, 16973815.
33. Hsia CCW, Hyde DM, Ochs M, Weibel ER. An official research policy statement of the american thoracic society / european respiratory society: standards for quantitative assessment of lung structure. Am J Respit Crit Care Med 2010, 181:394-418. 10.1164/rccm.200809-1522ST.
34. Fehrenbach H, Schepelmann D, Albes JM, Bando T, Fischer F, Fehrenbach A, Stolte N, Wahlers T, Richter J. Pulmonary ischemia/reperfusion injury: a quantitative study of structure and function in isolated heart-lungs of the rat. Anat Rec 1999, 255:84-89. 10.1002/(SICI)1097-0185(19990501)255:1<84::AID-AR10>3.0.CO;2-#, 10321996.
35. Fehrenbach A, Pufe T, Wittwer T, Nagib R, Dreyer N, Pech T, Petersen W, Fehrenbach H, Wahlers T, Richter J. Reduced vascular endothelial growth factor correlates with alveolar epithelial damage after experimental ischemia and reperfusion. J Heart Lung Transplant 2003, 22:967-978. 10.1016/S1053-2498(02)01157-9, 12957606.
36. Dreyer N, Mühlfeld C, Fehrenbach A, Pech T, von Berg S, Nagib R, Richer J, Wittwer T, Wahlers T, Ochs M. Exogenous surfactant application in a rat lung ischemia reperfusion injury model: effects on edema formation and alveolar type II cells. Resp Res 2008, 18;9(1):5. 10.1186/1465-9921-9-5.
37. Mühlfeld C, Müller K, Pallesen LP, Sandhaus T, Richter J, Wahlers T, Wittwer T, Ochs M. Impact of preservation solution on the extent of blood-air barrier damage and edema formation in experimental lung transplantation. Anat Rec 2007, 290:491-500. 10.1002/ar.20518.
38. Mason RJ, Williams MC. Type II alveolar cell. Defender of the alveolus. Am Rev Respir Dis 1977, 115:81-91. 326115.
39. Fehrenbach H. Alveolar epithelial type II cell: defender of the alveolus revisited. Respir Res 2001, 2:33-46. 10.1186/rr36, 11686863.
40. Mühlfeld C, Schaefer IM, Becker L, Bussinger C, Vollroth M, Bosch A, Madershahian N, Richter J, Wahlers T, Wittwer T, Ochs M. Preischemic exogenous surfactant reduces pulmonary injury in rat ischemia/reperfusion. Eur Resp J 2009, 33:625-633. 10.1183/09031936.00024108.
41. Mühlfeld C, Becker L, Bussinger C, Vollroth M, Nagib R, Schaefer IM, Knudsen L, Richter J, Madershahian N, Wahlers T, Wittwer T, Ochs M. Exogenous surfactant in ischemia/reperfusion: effects on endogenous surfactant pools. J Heart Lung Tansplant 2010, 29:327-334. 10.1016/j.healun.2009.07.019.
42. Knudsen L, Boxler L, Mühlfeld C, Schaefer IM, Becker L, Bussinger C, Stietencron I, Madershahian N, Richter J, Wahlers T, Wittwer T, Ochs M. Lung preservation in experimental ischemia/reperfusion injury and lung transplantation: a comparison of natural and synthetic surfactants. J Heart Lung Transplant 2012, 31:85-93. 10.1016/j.healun.2011.10.002, 22153552.
43. Wittwer T, Franke UFW, Madershahian M, Groetzner J, Strauch J, Wippermann J, Ochs M, Mühlfeld C, Börner A, Streck S, Wahlers T. Endobronchial donor pretreatment with Iloprost - is a second administration during reperfusion beneficial to optimize postischemic function of Non heart beating donor lungs?. J Surg Res 2006, 136:136-142. 10.1016/j.jss.2006.05.020, 16978652.
44. Wittwer T, Franke UFW, Sandhaus T, Thiene M, Groetzner J, Strauch JT, Wippermann J, Ochs M, Mühlfeld C, Wahlers T. Intravenous versus inhalative administration of Iloprost for donor lung pretreatment - which route is superior in experimental Pig lung transplantation?. Transplant Proc 2007, 39:1345-1349. 10.1016/j.transproceed.2007.03.065, 17580136.
45. Lee JW, Gupta N, Serikov V, Matthay MA. Potential application of mesenchymal stem cells in acute lung injury. Expert Opin Biol Ther 2009, 9:1259-1270. 10.1517/14712590903213651, 19691441.
46. Patel SA, Sherman L, Munoz J, Rameshvar P. Immunological properties of mesenchymal stem cells and clinical implications. Arch Immunol Ther Exp 2008, 56:1-8. 10.1007/s00005-008-0001-x.
47. D'Agostino B, Sullo N, Siniscalco D, De Angelis A, Rossi F. Mesenchymal stem cell therapy for the treatment of chronic obstructive pulmonary disease. Expert Opin Biol Ther 2010, 10:681-687. 10.1517/14712591003610614, 20384521.
48. Lee JW, Fang X, Gupta N. Allogenic human mesenchymal stem cells for treatment of E. coli endotoxin induced acute lung injury in the ex-vivo perfused human lung. Proc Natl Acad Sci U S A 2009, 106:16357-16362. 10.1073/pnas.0907996106, 19721001.
49. Yano T, Mason RJ, Pan T. KGF regulates pulmonary epithelial proliferation and surdfactant protein gene expression in adult rat lung. Am J Physiol Lung Cell Mol Physiol 2000, 279:L1146-L1158. 11076805.
50. Fang X, Neyrinck AP, Matthay MA, Lee JW. Allogeneic human mesenchymal stem cells restore epithelial protein permeability in cultured human alveolar type II cells by secretion of angiopoietin-1. J Biolog Chem 2010, 285:26211-26222. 10.1074/jbc.M110.119917.
51. Vanaudenaerde MB, Meyts I, Vos R, Geudens N, De Wever W, Verbeken EK, Van Raemdonck DE, Dupont LJ, Vreleden GM. A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy. Eur Respir J 2008, 32:832-843. 10.1183/09031936.00134307, 18827151.
52. Kelly K, Hertz MI. Obliterative bronchiolitis. Clin Chest Med 1997, 18:319-338. 10.1016/S0272-5231(05)70382-8, 9187825.
53. Badri L, Murray S, Liu LX, Walker NM, Flint A, Wadhwa A, Chan KM, Toews GB, Pinsky DJ, Martinez FJ. Mesenchymal stromal cells in bronchoalveolar lavage as predictors of bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2011, 183:1062-1070. 10.1164/rccm.201005-0742OC, 21169468.
54. Sato M, Waddell TK, Wagnetz U. Restrictive allograft syndrome (RAS): a novel form of chronic allograft dysfunction after lung transplantation. J Heart Lung Transplant 2011, 30:735-742. 10.1016/j.healun.2011.01.712, 21419659.
55. Sato M, Hwang DM, Wadell TK, Singer LG, Keshavjee S. Progression pattern of restrictive allograft syndrome after lung transplantation. J Heart Lung Transplant 2013, 32:23-30. 10.1016/j.healun.2012.09.026, 23260703.
56. Verleden GM, Vos R, Verleden SE. Survival determinants in lung transplant patients with chronic allograft dysfunction. Transplantation 2011, 92:703-708. 10.1097/TP.0b013e31822bf790, 21836537.
57. Sato M, Hirayama S, Matsuda Y. Stromal activation and formation of lymphoid-like stroma in chronic lung allograft dysfunction. Transplantation 2011, 91:1398-1405. 10.1097/TP.0b013e31821b2f7a, 21512432.
58. Gilpin SE, Lung KC, Sato M. Altered progenitor cell and cytokine profiles in bronchiolitis obliterans syndrome. J Heart Lung Transplant 2012, 31:222-228. 10.1016/j.healun.2011.11.012, 22305385.
59. Blum B, Benvenisty N. The tumorigenicity of human embryonic stem cells. Adv Cancer Res 2008, 100:133-158. 10.1016/S0065-230X(08)00005-5, 18620095.
60. Miura K, Okada Y, Aoi T, Okada A, Takahashi K, Okita K, Nakagawa M, Koyanagi M, Tanabe K, Ohnuki M, Ogawa D, Ikeda E, Okano H, Yamanaka S. Variation in the safety of induced pluripotent stem cell lines. Nat Biotechnol 2009, 27:743-745. 10.1038/nbt.1554, 19590502.
61. Moodley Y, Manuelpillai U, Weiss D. Cellular therapy for lung disease: a distant horizon. Respirology 2011, 16:223-223. 10.1111/j.1440-1843.2010.01914.x, 21199158.